FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022293527> ?p ?o ?g. }

• W2022293527 endingPage "222" @default.
• W2022293527 startingPage "212" @default.
• W2022293527 abstract "Objective.—To compare the efficacy and tolerability of sumatriptan nasal spray (NS) (5, 20 mg) versus placebo in the acute treatment of migraine in adolescent subjects. Background.—Currently, no triptan is approved in the United States for the treatment of migraine in adolescent subjects (12 to 17 years). In a previous randomized, placebo‐controlled study of 510 adolescent subjects, sumatriptan NS at 5, 10, and 20 mg doses was well tolerated. However, the primary efficacy analysis for headache relief with 20 mg at 2 hours did not demonstrate statistical significance ( P = .059). A second study was initiated to evaluate the efficacy of sumatriptan NS in this population. Methods.—This was a randomized (1:1:1), placebo‐controlled, double‐blind, parallel‐group study. Overall, 738 adolescent subjects (mean age: 14 years) with ≥6‐month history of migraine (with or without aura) self‐treated a single attack of moderate or severe migraine. The primary endpoints were headache relief at 1 hour and sustained relief from 1 to 24 hours. Pain‐free rates, presence/absence of associated symptoms, headache recurrence, and use of rescue medications were also assessed. Tolerability was based on adverse events (AEs) and vital signs. Results.—Sumatriptan NS 20 mg provided greater headache relief than placebo at 30 minutes (42% vs. 33%, respectively; P = .046) and 2 hours (68% vs. 58%; P = .025) postdose, but did not reach statistical significance at 1 hour (61% vs. 52%; P = .087) or for sustained headache relief from 1 to 24 hours ( P = .061). Significant differences ( P < .05) in favor of sumatriptan NS 20 mg over placebo were observed for several secondary efficacy endpoints including sustained relief from 2 to 24 hours. In general, sumatriptan NS 5 mg percentages were slightly higher than placebo but the differences did not reach statistical significance. Both doses of sumatriptan NS were well tolerated. No AEs were serious or led to study withdrawal. The most common event was taste disturbance (2%, placebo; 19%, sumatriptan NS 5 mg; 25%, sumatriptan NS 20 mg). Conclusions.—This study suggests that sumatriptan may be beneficial to some adolescents and is generally well tolerated in the acute treatment of migraine in this population." @default.
• W2022293527 created "2016-06-24" @default.
• W2022293527 creator A5011421741 @default.
• W2022293527 creator A5020607799 @default.
• W2022293527 creator A5049588760 @default.
• W2022293527 creator A5077870047 @default.
• W2022293527 creator A5085512930 @default.
• W2022293527 date "2006-02-01" @default.
• W2022293527 modified "2023-10-16" @default.
• W2022293527 title "Sumatriptan Nasal Spray in Adolescent Migraineurs: A Randomized, Double-Blind, Placebo-Controlled, Acute Study" @default.
• W2022293527 cites W1973426910 @default.
• W2022293527 cites W1976290551 @default.
• W2022293527 cites W2046482129 @default.
• W2022293527 cites W2051283521 @default.
• W2022293527 cites W2068370202 @default.
• W2022293527 cites W2074256173 @default.
• W2022293527 cites W2080324354 @default.
• W2022293527 cites W2111937143 @default.
• W2022293527 cites W2132805893 @default.
• W2022293527 cites W2141718894 @default.
• W2022293527 cites W2149133494 @default.
• W2022293527 cites W2151370984 @default.
• W2022293527 cites W2169042796 @default.
• W2022293527 cites W4233278386 @default.
• W2022293527 cites W49157362 @default.
• W2022293527 doi "https://doi.org/10.1111/j.1526-4610.2006.00339.x" @default.
• W2022293527 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16492230" @default.
• W2022293527 hasPublicationYear "2006" @default.
• W2022293527 type Work @default.
• W2022293527 sameAs 2022293527 @default.
• W2022293527 citedByCount "81" @default.
• W2022293527 countsByYear W20222935272012 @default.
• W2022293527 countsByYear W20222935272013 @default.
• W2022293527 countsByYear W20222935272015 @default.
• W2022293527 countsByYear W20222935272016 @default.
• W2022293527 countsByYear W20222935272017 @default.
• W2022293527 countsByYear W20222935272018 @default.
• W2022293527 countsByYear W20222935272019 @default.
• W2022293527 countsByYear W20222935272020 @default.
• W2022293527 countsByYear W20222935272021 @default.
• W2022293527 countsByYear W20222935272022 @default.
• W2022293527 countsByYear W20222935272023 @default.
• W2022293527 crossrefType "journal-article" @default.
• W2022293527 hasAuthorship W2022293527A5011421741 @default.
• W2022293527 hasAuthorship W2022293527A5020607799 @default.
• W2022293527 hasAuthorship W2022293527A5049588760 @default.
• W2022293527 hasAuthorship W2022293527A5077870047 @default.
• W2022293527 hasAuthorship W2022293527A5085512930 @default.
• W2022293527 hasConcept C126322002 @default.
• W2022293527 hasConcept C141071460 @default.
• W2022293527 hasConcept C142724271 @default.
• W2022293527 hasConcept C168563851 @default.
• W2022293527 hasConcept C170493617 @default.
• W2022293527 hasConcept C197934379 @default.
• W2022293527 hasConcept C203014093 @default.
• W2022293527 hasConcept C204787440 @default.
• W2022293527 hasConcept C27081682 @default.
• W2022293527 hasConcept C2777350023 @default.
• W2022293527 hasConcept C2777942821 @default.
• W2022293527 hasConcept C2778375690 @default.
• W2022293527 hasConcept C2778541695 @default.
• W2022293527 hasConcept C2778871607 @default.
• W2022293527 hasConcept C2778938600 @default.
• W2022293527 hasConcept C2780973058 @default.
• W2022293527 hasConcept C2908647359 @default.
• W2022293527 hasConcept C42219234 @default.
• W2022293527 hasConcept C65409693 @default.
• W2022293527 hasConcept C71924100 @default.
• W2022293527 hasConcept C85663871 @default.
• W2022293527 hasConcept C99454951 @default.
• W2022293527 hasConceptScore W2022293527C126322002 @default.
• W2022293527 hasConceptScore W2022293527C141071460 @default.
• W2022293527 hasConceptScore W2022293527C142724271 @default.
• W2022293527 hasConceptScore W2022293527C168563851 @default.
• W2022293527 hasConceptScore W2022293527C170493617 @default.
• W2022293527 hasConceptScore W2022293527C197934379 @default.
• W2022293527 hasConceptScore W2022293527C203014093 @default.
• W2022293527 hasConceptScore W2022293527C204787440 @default.
• W2022293527 hasConceptScore W2022293527C27081682 @default.
• W2022293527 hasConceptScore W2022293527C2777350023 @default.
• W2022293527 hasConceptScore W2022293527C2777942821 @default.
• W2022293527 hasConceptScore W2022293527C2778375690 @default.
• W2022293527 hasConceptScore W2022293527C2778541695 @default.
• W2022293527 hasConceptScore W2022293527C2778871607 @default.
• W2022293527 hasConceptScore W2022293527C2778938600 @default.
• W2022293527 hasConceptScore W2022293527C2780973058 @default.
• W2022293527 hasConceptScore W2022293527C2908647359 @default.
• W2022293527 hasConceptScore W2022293527C42219234 @default.
• W2022293527 hasConceptScore W2022293527C65409693 @default.
• W2022293527 hasConceptScore W2022293527C71924100 @default.
• W2022293527 hasConceptScore W2022293527C85663871 @default.
• W2022293527 hasConceptScore W2022293527C99454951 @default.
• W2022293527 hasIssue "2" @default.
• W2022293527 hasLocation W20222935271 @default.
• W2022293527 hasLocation W20222935272 @default.
• W2022293527 hasOpenAccess W2022293527 @default.
• W2022293527 hasPrimaryLocation W20222935271 @default.
• W2022293527 hasRelatedWork W1545409067 @default.

• next